4种口服保肝药治疗药物性肝损伤的有效性、安全性和经济性分析

发布时间：2018-02-25 09:04

本文关键词： 保肝药物药物性肝损伤疗效不良反应最小成本法　出处：《中国新药杂志》2017年08期 　论文类型：期刊论文

【摘要】：目的:对治疗药物性肝损伤的4种口服保肝药物进行有效、安全、经济性分析,为临床合理用药提供参考。方法:对2009年5月至2016年5月某医院263例药物性肝损伤患者用药进行回顾性分析,从药物疗效、不良反应及成本3个方面对4种口服保肝药物进行评价,并采用药物经济学分析方法,对4种口服保肝药的经济性进行比较。结果:药物疗效评价结果显示4种药物治疗药物性肝损伤临床疗效无统计学差异(P0.05);安全性评价结果显示4组患者不良反应发生率无显著差异(P0.05);药物成本比较结果显示甘草酸二铵成本最低,还原型谷胱甘肽成本最高;最小成本分析结果显示,甘草酸二铵的经济性较好。结论:4种口服保肝药治疗该医院263例药物性肝损伤患者的研究结果表明,不能证明其在临床疗效和不良反应发生率上有差异;在成本分析上,甘草酸二胺成本最低,还原型谷胱甘肽成本最高,最小成本分析结果显示甘草酸二胺的经济性较好。
[Abstract]:Objective: to analyze the efficacy, safety and economy of four kinds of oral hepatoprotective drugs in the treatment of drug-induced liver injury. Methods: from May 2009 to May 2016, 263 patients with drug-induced liver injury were analyzed retrospectively. Four kinds of oral hepatoprotective drugs were evaluated from three aspects of adverse reaction and cost, and the pharmacoeconomic analysis method was used. Results: there was no significant difference in the clinical efficacy of the four drugs in the treatment of drug-induced liver injury (P 0.05), and the safety evaluation showed that the 4 groups had adverse reactions. The cost of diammonium glycyrrhizinate was the lowest. The cost of reduced glutathione was the highest, and the results of minimum cost analysis showed that diammonium glycyrrhizinate was more economical. Conclusion the results of 263 patients with drug-induced liver injury treated with 4 kinds of oral liver-protective drugs are as follows:. In cost analysis, the cost of diamine glycyrrhizinate was the lowest, and the cost of reduced glutathione was the highest. The results of minimum cost analysis showed that diamine glycyrrhizinate was more economical.
【作者单位】：中国医院协会;北京中医药大学;中国食品药品检定研究院;北京市第六医院;
【分类号】：R575

【相似文献】